Navigation Links
ChemoCentryx Reports Additional New Data from the PROTECT-1 Study Demonstrating Traficet-EN's Effectiveness in Maintaining Remission in Patients with Crohn's Disease
Date:12/7/2009

inical response or remission, as well as maintaining response/remission in Crohn's disease over a combined total of 12 months. The 12-week Induction period of the study is followed by a 4-week, open-label period, during which all subjects receive Traficet-EN. Patients who achieve a pre-specified 70-point or greater reduction in CDAI are re-randomized to active drug or placebo for an additional 36-week Maintenance period, thereby permitting an evaluation of the drug's ability to maintain a treatment response. CDAI is a research tool used for determining a patient's level of disease activity and is the key measure regarded by regulatory agencies as an appropriate endpoint to assess the efficacy of a drug for the treatment of Crohn's disease.

Study Results and Methods for CCR9 and TECK in Large Bowel Inflammatory Bowel Disease

In studies done to test the prevailing notion that TECK protein and CCR9 only function in the small bowel, ChemoCentryx scientists demonstrated TECK protein is readily detectable in human colon samples from both normal subjects and patients with IBD. Furthermore, they assessed colonic tissues from mice which spontaneously develop inflammatory colitis owing to a genetic predisposition. TECK chemokine expression within the colon of pre-symptomatic mice were significantly increased compared to control, normal, mice (0.2 +/- 0.09 pg/ug protein and 0.04 +/- 0.0006 pg/ug protein, respectively; p </= 0.05) and furthermore, in mice displaying severe symptoms, TECK levels were significantly increased compared to pre-symptomatic animals (16.51 +/- 3.9 pg/ug protein; p</=0.05 vs pre-symptomatic mice). Also, pharmacologic inhibition of CCR9 in these animals resulted in marked reduction of their colitis.

About Traficet-EN(TM) (CCX282-B)

Traficet-EN is a small molecule, orally bioavailable drug that is administered in capsule form and which is believed to control the inappropriate immune s
'/>"/>

SOURCE ChemoCentryx, Inc.
Copyright©2009 PR Newswire.
All rights reserved

Page: 1 2 3 4 5 6 7

Related medicine technology :

1. ChemoCentryx Reports Positive PROTECT-1 Study Results for Traficet-EN(TM) at the GASTRO 2009 UEGW/WCOG Conference
2. PROTECT-1 Phase II/III Induction-Stage Results for ChemoCentryxs Traficet-EN(TM) Presented in Oral Session at DDW 2009 Conference
3. ChemoCentryx Completes Enrollment of PROTECT-1, a Phase II/III Clinical Trial of CCR9 Antagonist CCX282-B (Traficet-EN(TM)) in Crohns Disease
4. ChemoCentryx Initiates Clinical Trial of CCR1 Inhibitor CCX354
5. Keryx Biopharmaceuticals, Inc. Reports Updated Phase 1/2 Data, Including New Survival Data, on KRX-0401 (Perifosine) in the Treatment of Advanced Multiple Myeloma at the 51st Annual Meeting of the American Society of Hematology
6. TaiGen Biotechnology Reports Phase I and Preclinical Data for TG-0054 at the 2009 American Society of Hematology (ASH) Annual Meeting
7. Quigley CEO, Ted Karkus, Announces Phase One of 2010 Strategic Plan; Karkus Reports that the Primary Focus will be on Leveraging its OTC Platform; Company Aggressively Seeking Product Acquisitions and Line Extensions which Leverage its Distribution
8. Dermagen Reports Successful Phase I/IIa Clinical Trial for Atopic Dermatitis
9. NOVAVAX Reports Positive Clinical Results from Pivotal Study of H1N1 Influenza Vaccine in Mexico
10. ADVENTRX Pharmaceuticals Reports Additional Pre-Clinical Data for ANX-514
11. Pharmasset Reports Fiscal Year End 2009 Financial Results
Post Your Comments:
*Name:
*Comment:
*Email:
(Date:12/17/2014)... 17, 2014  RXi Pharmaceuticals Corporation (NASDAQ: ... discovering, developing and commercializing innovative therapies addressing major ... of enrollment in its first Phase 2a study, ... confirmed the 1-month findings that were reported in ... - http://photos.prnewswire.com/prnh/20130917/NE80755LOGO , , ...
(Date:12/15/2014)... --Research and Markets ( http://www.researchandmarkets.com/research/bf3b6l/electrocardiogram ) has ... - Global Trends, Estimates and Forecasts, 2012-2018" report ... Global Electrocardiogram Devices (ECG) sector is ... North America accounts for nearly 36% ... Europe claims approximately 27% (2018). ...
(Date:12/15/2014)... , Dec. 15, 2014  Inovio Pharmaceuticals, Inc. ... has been added to the NASDAQ Biotechnology Index ... will become effective upon market open on December ... is designed to track the performance of a ... either biotechnology or pharmaceutical according to the Industry ...
Breaking Medicine Technology:RXi Pharmaceuticals Announces Sustained Effect of RXI-109 at Three Months Post Scar Revision Surgery and the Completion of Enrollment for its Phase 2a Trial RXI-109-1301 2RXi Pharmaceuticals Announces Sustained Effect of RXI-109 at Three Months Post Scar Revision Surgery and the Completion of Enrollment for its Phase 2a Trial RXI-109-1301 3RXi Pharmaceuticals Announces Sustained Effect of RXI-109 at Three Months Post Scar Revision Surgery and the Completion of Enrollment for its Phase 2a Trial RXI-109-1301 4RXi Pharmaceuticals Announces Sustained Effect of RXI-109 at Three Months Post Scar Revision Surgery and the Completion of Enrollment for its Phase 2a Trial RXI-109-1301 5Electrocardiogram (ECG) Devices - Global Trends, Estimates and Forecasts, 2012-2018 2Electrocardiogram (ECG) Devices - Global Trends, Estimates and Forecasts, 2012-2018 3Electrocardiogram (ECG) Devices - Global Trends, Estimates and Forecasts, 2012-2018 4Inovio Pharmaceuticals Added to NASDAQ Biotechnology Index 2Inovio Pharmaceuticals Added to NASDAQ Biotechnology Index 3Inovio Pharmaceuticals Added to NASDAQ Biotechnology Index 4
... 18, 2011 What:   ... analysis of FDA,s 510(k) regulatory pathway—through which more than ... within it. The study is the most comprehensive survey ... FDA,s Center for Devices and Radiological Health (CDRH) is ...
... DIEGO, May 18, 2011 aTyr Pharma ... that Melissa Ashlock, M.D., has joined as vice ... Ashlock,s experience in translating novel biology into drug ... team in the development of innovative therapeutic approaches ...
Cached Medicine Technology:Findings From Largest Industry Assessment of 510(k) Process to be Released on May 24, 2011 2Translational Science Expert, Dr. Melissa Ashlock, Joins aTyr Pharma to Advance Physiocrine-based Therapeutics 2Translational Science Expert, Dr. Melissa Ashlock, Joins aTyr Pharma to Advance Physiocrine-based Therapeutics 3
(Date:12/19/2014)... Hands On Mobile Spa, has announced they now have a ... been transformed into a utopia for the Long Island community ... The Virtual Tour showcases the beauty of the Spa On ... more. , The Virtual Tour shows viewers each of the ... overhauled Winnebago. Marla Kaplan-Pelle, Director states " It's hard to ...
(Date:12/19/2014)... December 19, 2014 After a 13-year ... is again returning to the stage to entertain his ... for concert performances, and the successful tour has been ... announced. , Visit Ticketability.com for a ... Detroit shows at fair prices. , Music fans have ...
(Date:12/19/2014)... Dec. 18, 2014 (HealthDay News) -- A new study ... moderate to severe hot flashes and night sweats -- ... Hot flashes are common during menopause, affecting about ... also affect women after menopause, since they then face ... "Our findings suggest women who exhibit moderate or severe ...
(Date:12/19/2014)... News) -- Prostaglandin analogue eye drops -- a common ... of vision loss in patients with the eye disease, ... David Garway-Heath, of the Moorfields Eye Hospital and UCL ... than 500 people newly diagnosed with open-angle glaucoma -- ... of the leading causes of blindness. About 45 ...
(Date:12/17/2014)... RI (PRWEB) December 17, 2014 ... recognize private practices that have made outstanding and ... in support and progression of private practice physical ... American Physical Therapy Association. , On behalf of ... OCS, owner and CEO of Performance accepted the ...
Breaking Medicine News(10 mins):Health News:A Virtual Tour Of Hands On Mobile Massage Spa Is Now Available 2Health News:A Virtual Tour Of Hands On Mobile Massage Spa Is Now Available 3Health News:Garth Brooks Tickets for Joe Louis Arena: Ticketability.com Becomes a Popular Destination for Discount Tickets for Garth Brooks’ Detroit Concerts Set for February 27-28 2Health News:Severe Hot Flashes During Menopause May Raise Hip Fracture Risk Later: Study 2Health News:Study Supports Benefit of Widely Used Glaucoma Drug 2Health News:Performance Physical Therapy Awarded with Jayne L. Snyder Private Practice of the Year 2014 2
... minister Andy Kerr has ordered the closure of two hospitals ... close the hospitals in the border as part of a ... the 80-year-old nine-bed Queen Margaret Hospital in Jedburgh and the ... worked hard to save the community hospitals. The Jedburgh Provost ...
... of laws was initiated by Quebec Health Minister Philippe Couillard ... health-care insurance //. ,The Supreme Court of Canada ... on June 9, 2005,ruling that Quebec had failed to prove ... medicare, was justified. However with the development of Bill ...
... fast-growing medical tourism industry is set to get a ... the entire range of medicare facilities overseas//. ,Global ... a leading travel firm, have signed an agreement to ... Africa, Canada and the Middle East. ...
... study has shed light on a different dimension to ... during childhood. // Insecure feelings experienced during childhood and ... of one’s body that can translate into an eating ... very early due to insecure attachment and separation anxiety. ...
... women, women overweight in their teens or later are at ... was conducted by scientists at the University of Pittsburgh Medical ... 2,110 women with and without ovarian cancer. The study of ... in recent years or at the age of 18, were ...
... boy’s divorced parents, whether to circumcise their son or not. ... inflammation in last year, his mother needs her son to be ... is fine and if circumcision was done it will result in ... 2003 divorce decree has given the rights to decide on the ...
Cached Medicine News:Health News:Quebecers To Choose Private Health-Care Insurance 2Health News:Plan to Promote the Medicare Facilities of India to Abroad 2
Used for introducing a Foley catheter (up to 18.0 French in size) suprapubically into the bladder. Supplied sterile in peel-open packages. Intended for one-time use....
Used to establish and temporarily maintain suprapubic access during endoscopic procedures. Supplied sterile in peel-open packages. Intended for one-time use....
Used for pulling sutures from a vaginal incision into the suprapubic area during bladder suspension surgery. Supplied sterile in peel-open packages....
Stratasis Urethral Sling is intended for implantation to reinforce soft tissues where weakness exists. Supplied sterile in peel-open packages. Intended for one-time use....
Medicine Products: